Rapamycin (sirolimus) is an mTORC1 inhibitor with potent autophagy-inducing and immunomodulatory properties that has emerged as one of the most mechanistically compelling pharmacological interventions for tauopathies](/mechanisms/tauopathies). Originally isolated from Streptomyces hygroscopicus in soil from Easter Island (Rapa Nui) and developed as an immunosuppressant for organ transplantation, rapamycin gained attention in geroscience when it became the first drug to consistently extend lifespan in genetically heterogeneous mice across multiple independent studies. Its primary neuroprotective mechanism — autophagy induction through mTORC1 inhibition — directly targets the accumulation of [hyperphosphorylated tau](/mechanisms/tau-phosphorylation) aggregates that define corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and other [4R-tauopathies](/mechanisms/4r-tau-cbs).
The Participatory Evaluation (of) Aging (with) Rapamycin for Longevity (PEARL) trial and related geroscience trials are generating human safety and biomarker data at low, intermittent doses that differ fundamentally from the high-dose continuous immunosuppression used in transplant medicine. For CBS/PSP patients, rapamycin's simultaneous capacity to enhance autophagy, reduce neuroinflammation, improve mitochondrial function via mitophagy, and potentially slow cellular senescence makes it a multi-target intervention addressing several key pathological mechanisms.
¶ Historical Context and Discovery
¶ From Easter Island to Geroscience
The story of rapamycin is one of the most remarkable in pharmaceutical history. In 1964, a Canadian expedition to Easter Island (Rapa Nui) collected soil samples that were later found to contain Streptomyces hygroscopicus, a bacterium producing a potent antifungal compound. Suren Sehgal at Ayerst Laboratories isolated and characterized the compound in 1972, naming it rapamycin after its origin island. Despite initial development for antifungal use, its immunosuppressive properties led to FDA approval in 1999 as sirolimus for prevention of kidney transplant rejection[@li2014].
The transformative discovery for aging research came in 2009, when the National Institute on Aging's Interventions Testing Program (ITP) demonstrated that rapamycin extended median lifespan by 9% in male and 14% in female genetically heterogeneous mice, even when treatment began at 20 months of age (equivalent to approximately 60 human years)[@harrison2009]. This was the first pharmacological intervention to extend lifespan in a genetically diverse mammalian model — and critically, late-life initiation worked, making it relevant to patients already diagnosed with neurodegenerative disease.
Rapamycin's mechanism illuminated the fundamental biology of autophagy — a process recognized by the 2016 Nobel Prize in Physiology or Medicine awarded to Yoshinori Ohsumi. The demonstration that mTORC1 inhibition activates autophagy through ULK1 and TFEB provided the mechanistic basis for rapamycin's potential in proteinopathies, where accumulated misfolded proteins (tau, amyloid-beta, alpha-synuclein) represent autophagy substrates that the aging brain fails to clear[@menzies2017].
¶ Current Clinical Landscape
As of 2026, rapamycin/sirolimus is:
¶ mTOR Signaling and Neurodegeneration
mTOR (mechanistic target of rapamycin) functions as a central nutrient-sensing kinase that coordinates cell growth, protein synthesis, and autophagy. mTOR exists in two complexes[@saxton2017]:
mTORC1 (rapamycin-sensitive):
mTORC2 (partially rapamycin-resistant):
In the healthy brain, mTORC1 activity is balanced — allowing protein synthesis for synaptic plasticity while maintaining basal autophagy. In [neurodegenerative tauopathies](/mechanisms/tauopathies), mTORC1 is hyperactivated by tau pathology](/mechanisms/tau-pathology) itself, creating a vicious cycle: tau aggregates](/mechanisms/tau-aggregation) activate mTORC1, which suppresses autophagy, which allows further tau accumulation](/mechanisms/tau-pathology)[@hoglinger2014].
graph TD
A["Tau Aggregation"] --> B["mTORC1 Hyperactivation"]
B --> C["ULK1 Phosphorylation<br/>Ser757 → Autophagy OFF"]
B --> D["TFEB Cytoplasmic<br/>Retention, Lysosome Down"]
B --> E["S6K1 Activation<br/>→ Excess protein synthesis"]
C --> F["Autophagy Suppressed"]
D --> F
F --> G["Tau Accumulates Further"]
G --> A
H["RAPAMYCIN"] -->|"FKBP12 binding"| I["mTORC1 Inhibition"]
I --> J["ULK1 Dephosphorylation<br/>→ Autophagy ON"]
I --> K["TFEB Nuclear<br/>Translocation, Lysosome Up"]
I --> L["S6K1 Inhibition<br/>→ Balanced synthesis"]
J --> M["Autophagosome Formation"]
K --> N["Lysosomal Biogenesis<br/>Cathepsin D, LAMP1 Up"]
M --> O["Tau Aggregate<br/>Clearance"]
N --> O
I --> P["Anti-Inflammatory<br/>mTORC1 in microglia Down"]
I --> Q["Mitophagy Enhanced<br/>PINK1/Parkin activated"]
I --> R["Senescence Slowed<br/>SASP reduced"]
O --> S["NEUROPROTECTION"]
P --> S
Q --> S
R --> S
style A fill:#ffcdd2
style H fill:#e1f5fe
style S fill:#c8e6c9
style F fill:#fff3e0
Post-mortem brain studies demonstrate elevated mTORC1 pathway activity in tauopathies:
- PSP brains: Increased p-mTOR (Ser2448), p-S6K1, and p-4E-BP1 immunoreactivity in neurons and glial cells of affected regions (frontal cortex, subthalamic nucleus, midbrain)[@hoglinger2014]
- CBD brains: Elevated p-S6 ribosomal protein in neurons with tau pathology
- AD brains: mTORC1 hyperactivation correlates with Braak stage and tau tangle density[@caccamo2010]
- Mechanism: Tau oligomers activate PI3K/Akt, which phosphorylates and inactivates TSC1/TSC2, releasing mTORC1 from tonic inhibition
Rapamycin binds the intracellular immunophilin FKBP12, and the rapamycin-FKBP12 complex allosterically inhibits mTORC1 by binding to the FRB domain of mTOR[@li2014]. mTORC1 inhibition activates autophagy through:
- ULK1 complex activation: Dephosphorylated ULK1 (at Ser757) associates with ATG13 and FIP200, initiating phagophore nucleation[@kim2011]
- VPS34 complex activation: PI3K class III generates PI3P on the ER membrane, recruiting autophagy machinery
- ATG5-ATG12-ATG16L1 conjugation: Membrane elongation and LC3 lipidation (LC3-I → LC3-II)
- TFEB nuclear translocation: mTORC1 normally phosphorylates TFEB (Ser211), keeping it cytoplasmic. Rapamycin-mediated mTORC1 inhibition allows TFEB nuclear entry, upregulating a coordinated network of autophagy and lysosomal genes[@settembre2011]
- Autophagosome-lysosome fusion: SNARE-mediated fusion delivers cargo to lysosomes for degradation
Tau aggregates (oligomers, paired helical filaments, straight filaments) are primarily degraded by macroautophagy rather than the ubiquitin-proteasome system[@menzies2017]. Key evidence:
- Rapamycin reduces tau in P301L mice: Caccamo and colleagues demonstrated that rapamycin treatment in 3xTg-AD mice (carrying MAPT P301L) reduced both soluble and insoluble tau by 40–50%, with concurrent increase in LC3-II and decrease in p62, confirming autophagy enhancement[@caccamo2010a]
- TFEB overexpression clears tau: Viral TFEB expression in rTg4510 mice (P301L tau) reduced PHF-tau by 60% and rescued neurodegeneration[@polito2014]
- Autophagy deficiency worsens tau: Conditional ATG7 knockout in tau transgenic mice accelerated tau accumulation and neurodegeneration, confirming autophagy's essential role[@inoue2012]
- 4R-tau specificity: 4R-tau aggregates (predominant in CBS/PSP) show greater dependence on autophagy (vs. proteasomal) clearance compared to 3R-tau aggregates, potentially making mTORC1 inhibition more effective in 4R-tauopathies
Beyond autophagy, rapamycin modulates neuroinflammation through mTORC1's role in immune cell function:
- Microglial mTORC1: mTORC1 is activated in pro-inflammatory microglia; rapamycin shifts microglia toward anti-inflammatory/phagocytic phenotype, potentially enhancing extracellular tau clearance[@dello2013]
- T-cell modulation: Low-dose rapamycin paradoxically enhances CD8+ T-cell memory formation while suppressing inflammatory T-cell responses — the immunological basis for intermittent dosing[@araki2009]
- SASP reduction: mTORC1 drives SASP production in senescent cells; rapamycin reduces SASP without eliminating senescent cells, complementing senolytic approaches[@laberge2015]
- Astrocyte reactivity: mTORC1 inhibition reduces reactive astrogliosis and GFAP upregulation in neurodegeneration models
Rapamycin promotes selective autophagy of damaged mitochondria (mitophagy) through:
- PINK1/Parkin pathway activation: mTORC1 inhibition enhances PINK1 stabilization on depolarized mitochondria, recruiting Parkin for ubiquitin-mediated mitophagy[@bartolome2017]
- BNIP3L/Nix upregulation: TFEB activation increases expression of mitophagy receptors
- Mitochondrial quality control: By clearing dysfunctional mitochondria, rapamycin reduces the ROS burden that drives tau phosphorylation
This is particularly relevant to PSP, where Complex I deficiency and mitochondrial dysfunction are well-documented[@albers2001].
Caccamo et al. (2010) provided the foundational evidence[@caccamo2010a]:
- Protocol: Rapamycin 2.24 mg/kg/day in diet, initiated at 2 months (before pathology) or 15 months (established pathology)
- Early treatment: Prevented tau hyperphosphorylation, NFT formation, and cognitive decline
- Late treatment: Reduced existing tau pathology by 40%, improved memory on Morris water maze
- Mechanism confirmation: LC3-II increased 2.5-fold; p62 decreased 60%; mTORC1 activity (p-S6K1) reduced 80%
Frederick et al. demonstrated that rapamycin reduced neurodegeneration even after established tau pathology in this aggressive tauopathy model[@frederick2015]:
- 4 weeks of rapamycin treatment reduced hippocampal volume loss by 35%
- Decreased microglial activation (Iba1 area) by 50%
- Reduced insoluble tau by 30%
- Effects were autophagy-dependent (abolished by chloroquine co-treatment)
Ozcelik et al. showed rapamycin restored autophagy in PS19 mice[@ozcelik2013]:
- Reversed mTORC1 hyperactivation in cortex and hippocampus
- Cleared both oligomeric and fibrillar tau species
- Preserved synaptic density (synaptophysin) and prevented neuronal loss
- Improved grip strength and motor coordination
¶ Dose-Response and Intermittent Dosing
Preclinical dose-response studies suggest that intermittent rapamycin dosing (e.g., 3×/week) achieves equivalent autophagy induction with fewer metabolic side effects compared to daily dosing[@dumas2021]:
- Weekly rapamycin: Sufficient to maintain elevated autophagy markers for 5–7 days after a single dose in mice
- Metabolic safety: Intermittent dosing avoids sustained mTORC2 inhibition that causes insulin resistance and dyslipidemia
- Immune function: Paradoxically, intermittent low-dose rapamycin enhances immune function (vaccine responses) rather than suppressing it
¶ Clinical Evidence and Trials
The Participatory Evaluation (of) Aging (with) Rapamycin for Longevity (PEARL) trial is a pioneering citizen science initiative testing low-dose rapamycin for aging[@bitto2016]:
- Design: Observational/quasi-experimental; participants take rapamycin under physician supervision
- Dose: Typically 5–6 mg once weekly (intermittent, not daily)
- Findings to date: No significant immunosuppression; improved metabolic markers in some participants; favorable safety profile at low intermittent doses
- Relevance: Establishes feasibility and safety of low-dose rapamycin in older adults — the population relevant to CBS/PSP
Two landmark trials established that mTOR inhibition (everolimus, a rapamycin analog) enhanced immune function in older adults[@mannick2014]:
- 2014 trial: Everolimus 0.5 mg daily or 5 mg weekly for 6 weeks in adults ≥65 years improved influenza vaccine response by 20%
- 2018 trial: Low-dose everolimus + a catalytic mTOR inhibitor reduced infection rates by 30% in older adults over 16 weeks
- These trials demonstrated that low-dose mTOR inhibition enhances rather than suppresses immune function — overturning the concern that rapamycin would increase infection risk
| Trial |
Condition |
Agent |
Phase |
Status |
| NCT04629495 |
AD |
Rapamycin 1 mg daily |
Phase II |
Recruiting |
| NCT04200911 |
ALS |
Rapamycin 2 mg daily |
Phase I |
Completed (Phase I only) |
| NCT05915091 |
Aging |
Rapamycin 5-10 mg weekly |
Phase II |
Recruiting |
No CBS/PSP-specific rapamycin trials exist, representing a critical gap.
CBS and PSP are defined by accumulation of 4R-tau in disease-specific patterns. Several features make them particularly amenable to rapamycin-mediated autophagy:
- mTORC1 hyperactivation: Documented in PSP post-mortem tissue — rapamycin directly addresses this pathological activation[@hoglinger2014]
- Autophagy-lysosomal dysfunction: PSP brains show reduced TFEB nuclear levels, decreased cathepsin D, and p62 accumulation[@piras2016]
- 4R-tau filament properties: Straight filaments (PSP) and CBD-type filaments are primarily cleared by macroautophagy, not proteasomal degradation
- MAPT H1 haplotype: The H1/H1 genotype increases 4R-tau expression; autophagy enhancement may compensate for this genetic overproduction[@hglinger2011]
- Astrocytic tau: Tufted astrocytes (PSP) and astrocytic plaques (CBD) involve glial tau accumulation, where autophagy is less efficient. Rapamycin activates autophagy in both neurons and glia
Rapamycin's systemic distribution means it reaches all brain regions, including deep structures (midbrain, subthalamic nucleus) affected in PSP that are inaccessible to topical therapies like photobiomodulation. This is a significant advantage for PSP, where pathology concentrates in subcortical structures.
Rapamycin simultaneously addresses:
- Protein aggregation: Autophagy clears tau
- Neuroinflammation: Microglial modulation
- Mitochondrial dysfunction: Mitophagy
- Cellular senescence: SASP reduction
- Aging itself: Geroscience target
Based on PEARL and geroscience trial data:
| Parameter |
Recommendation |
| Drug |
Rapamycin (sirolimus) 1 mg tablets |
| Dose |
5–6 mg once weekly OR 1 mg every other day |
| Timing |
Morning, consistent day each week |
| Food interaction |
Take consistently with or without food (food increases Cmax but does not affect AUC) |
| Duration |
Minimum 6 months for assessment; potentially lifelong if tolerated |
| Blood levels |
Target trough <5 ng/mL (well below immunosuppressive range of 10–20 ng/mL) |
| Week |
Dose |
Monitoring |
| 1–2 |
2 mg weekly |
Baseline labs, tolerability assessment |
| 3–4 |
4 mg weekly |
CBC, CMP, lipid panel, fasting glucose |
| 5+ |
5–6 mg weekly (target) |
Monthly labs for 3 months, then quarterly |
Before starting: CBC with differential, CMP, fasting lipid panel, fasting glucose/HbA1c, rapamycin trough level baseline
Monthly (first 3 months): CBC, CMP, fasting glucose, lipid panel, rapamycin trough level
Quarterly (maintenance): Same as monthly; add HbA1c
Clinical: Cognitive testing (MoCA, FAB), PSPRS or CBD scale every 3 months
¶ Safety and Adverse Effects
The safety profile at geroscience doses (5–6 mg/week) is fundamentally different from transplant doses (2–5 mg/day)[@kraig2018]:
- Mouth sores/stomatitis: Most common side effect (15–20%); usually mild, dose-dependent, managed with corticosteroid mouthwash
- Hyperlipidemia: LDL and triglyceride elevation in 10–15%; usually mild; may require statin if persistent
- Hyperglycemia: Mild fasting glucose elevation in 5–10%; monitor in pre-diabetic patients
- Immunosuppression: NOT observed at low intermittent doses; paradoxical immune enhancement documented[@mannick2014]
- Wound healing: Theoretical concern; avoid starting within 2 weeks of planned surgery
- Severe hepatic impairment (rapamycin is hepatically metabolized via CYP3A4)
- Active, untreated infection
- Concurrent strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) — dramatically increase rapamycin levels
- Uncontrolled diabetes (fasting glucose >200 mg/dL)
- Pregnancy/breastfeeding
- CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors): Increase rapamycin levels — dose reduction or avoidance required
- CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort): Decrease rapamycin levels
- Grapefruit juice: Increases absorption — avoid or use consistently
- Compatible with: Levodopa, amantadine, SSRIs, memantine, cholinesterase inhibitors, most CBS/PSP medications
Rapamycin's mTORC1-dependent mechanism is orthogonal to several other autophagy and neuroprotection pathways:
| Combination |
Mechanism |
Rationale |
| Rapamycin + Spermidine |
mTORC1 + EP300 |
Dual autophagy via independent pathways; additive effect demonstrated[@bhukel2017] |
| Rapamycin + Lithium |
mTORC1 + IMPase |
mTOR-dependent + mTOR-independent autophagy; GSK-3β inhibition |
| Rapamycin + TUDCA |
Autophagy + ER stress |
Protein clearance + folding quality control |
| Rapamycin + Urolithin A |
General autophagy + selective mitophagy |
Complementary clearance pathways |
| Rapamycin + NAD+ precursors |
mTORC1 + sirtuins |
Autophagy + metabolic support |
| Rapamycin + Metformin |
mTORC1 + AMPK |
Dual nutrient sensing; potential synergy or dose reduction |
¶ Caregiver and Patient Education
For CBS/PSP patients and caregivers considering rapamycin:
- Expectation setting: Rapamycin is not a cure — it may slow progression by enhancing cellular cleanup. Benefits may take months to manifest and are likely subtle
- Side effect management: Mouth sores are the most common nuisance; prophylactic swish-and-spit dexamethasone mouthwash can prevent or reduce them
- Blood monitoring: Regular blood draws are essential for the first 6 months; explain the rationale (glucose, lipids, blood counts) to maintain compliance
- Infection awareness: Although low-dose rapamycin does not immunosuppress, patients should report fever, prolonged cough, or unusual infections promptly
- Drug interactions: Patients must inform all prescribers about rapamycin use, particularly before any new antibiotic or antifungal prescription
- Cost and access: Generic sirolimus is affordable; prescribing physician may need to document off-label rationale for insurance; some geroscience-focused clinics specialize in rapamycin prescribing
¶ Clinical Decision Triggers and Stop Rules
Given limited tauopathy-specific human efficacy data, rapamycin use in CBS/PSP should be treated as a monitored disease-modification experiment rather than routine care.
| Scenario |
Suggested action |
| Stable labs, no grade 2+ adverse effects, tolerated oral intake |
Continue current intermittent dose and reassess every 12 weeks |
| Persistent grade 1 stomatitis, LDL rise, or mild fasting glucose drift |
Reduce dose by 25-50% and add targeted supportive measures |
| Recurrent infections, ANC decline, non-healing wounds, severe mucositis, or sustained HbA1c worsening |
Hold rapamycin, investigate reversible contributors, restart only if risk-benefit remains favorable |
| Major surgery planned |
Pause 1-2 weeks pre-op and restart only after wound-healing stability |
- Define baseline goals before starting (mobility, swallowing safety, caregiver burden, PSPRS trend, or cognitive trajectory).
- Use a pre-specified review interval (for example 3 and 6 months) with explicit success/futility thresholds.
- Document which outcomes matter most to the patient and caregiver (fall rate, aspiration events, communication burden, independence in ADLs).
- Stop if burden consistently outweighs perceived benefit despite dose/schedule optimization.
| Dimension |
Score |
Rationale |
| Mechanistic Clarity |
9/10 |
mTORC1-autophagy-tau clearance pathway precisely defined |
| Clinical Evidence |
4/10 |
PEARL + immune aging trials; no tauopathy-specific RCTs |
| Preclinical Evidence |
9/10 |
Strong evidence across multiple tau mouse models |
| Replication |
7/10 |
Tau clearance replicated in 3xTg-AD, rTg4510, PS19 by independent groups |
| Effect Size |
7/10 |
30–50% tau reduction in mice; substantial neuronal preservation |
| Safety/Tolerability |
6/10 |
Favorable at low doses; requires monitoring; mouth sores common |
| Biological Plausibility |
9/10 |
mTORC1 hyperactivation documented in PSP; autophagy deficiency established |
| Actionability |
6/10 |
Prescription required; needs physician supervision; affordable (generic) |
| Total |
57/80 |
|
¶ Research Gaps and Future Directions
- No CBS/PSP trial: The most glaring gap — a Phase Ib/II trial of weekly rapamycin in PSP-Richardson syndrome with tau PET and NfL endpoints would be transformative
- Dose optimization for CNS: Whether 5 mg/week achieves therapeutic mTORC1 inhibition in human brain is unknown; CSF rapamycin levels have not been measured at low doses
- mTORC2 effects: Chronic exposure may inhibit mTORC2, affecting insulin signaling and cytoskeleton — needs monitoring in long-term treatment
- Biomarker response: Whether rapamycin reduces CSF p-tau-181/217 or plasma NfL in humans is unknown
- Rapalogs comparison: Everolimus (oral, shorter half-life) and temsirolimus (IV) may offer advantages; head-to-head comparison needed
- Aging interaction: Since rapamycin extends lifespan in mice, it may have disease-modifying effects beyond tau clearance in aging CBS/PSP patients[@kaeberlein2019]
- Drug holiday protocols: Optimal intermittent dosing schedule (weekly vs. biweekly vs. 2-weeks-on/2-weeks-off) needs optimization[@arriola2016]
Priority trial design: Adaptive Phase Ib/II of rapamycin 5 mg weekly in 40 PSP-Richardson syndrome patients, with tau PET (18F-MK-6240), plasma p-tau-217, NfL, and PSPRS as co-primary endpoints, over 12 months.
Several rapamycin analogs (rapalogs) may offer pharmacological advantages for neurodegenerative applications:
Everolimus has improved oral bioavailability (20% vs. 14% for rapamycin) and shorter half-life (30h vs. 62h), potentially allowing more precise dosing[@kirchner2004]. The Mannick immune aging trials used everolimus at 0.5 mg daily, establishing safety in older adults. Everolimus is FDA-approved for tuberous sclerosis complex (TSC), demonstrating CNS mTORC1 inhibition with imaging-confirmed tumor reduction in brain subependymal giant cell astrocytomas.
Available as IV formulation, temsirolimus achieves more consistent brain exposure than oral rapamycin. Frederick et al. demonstrated that temsirolimus reduced tau pathology in mutant tau transgenic mice with effects comparable to rapamycin[@frederick2015]. However, IV administration limits its practicality for chronic neurodegenerative disease management.
Catalytic mTOR inhibitors (Torin1, AZD2014/vistusertib) inhibit both mTORC1 and mTORC2, producing more complete autophagy induction but also greater metabolic disruption. These agents are under investigation in oncology but have not been tested in neurodegenerative disease. For CBS/PSP, the selective mTORC1 inhibition of rapamycin/rapalogs is preferred due to better safety margins[@thoreen2009].
Rapamycin occupies a unique position in the CBS/PSP treatment landscape because it addresses aging itself — the strongest risk factor for both diseases. The geroscience hypothesis posits that interventions targeting fundamental aging mechanisms (mTORC1 signaling, cellular senescence, mitochondrial dysfunction, epigenetic alterations) can simultaneously delay multiple age-related diseases[@harrison2009]. For CBS/PSP patients:
- Disease-modifying: Autophagy enhancement addresses the proximate cause (tau accumulation)
- Aging-modifying: mTORC1 inhibition addresses the underlying biological aging that permitted disease emergence
- Multi-morbidity benefit: Many CBS/PSP patients have concurrent cardiovascular disease, metabolic syndrome, or cancer risk — rapamycin may provide co-benefits for these conditions
- Lifespan data: Rapamycin extends lifespan 9–14% in genetically diverse mice even when started at 20 months (equivalent to ~60 years human age)[@harrison2009]. Whether this translates to human survival benefit in CBS/PSP is unknown but biologically plausible.
Rapamycin tablets (0.5 mg, 1 mg, 2 mg) can be:
- Dispersed in water (takes 2–3 minutes to dissolve)
- Administered via oral syringe in thickened liquid
- Given via PEG tube if needed in advanced disease (crush and dissolve)
Rapamycin does not cause orthostatic hypotension or sedation, making it compatible with the high fall-risk profile of PSP patients. However, mouth sores may reduce oral intake, potentially causing dehydration-related falls — monitor hydration closely.
Before starting rapamycin, review the medication list for:
- CYP3A4 interactions (most common issue)
- Statin dose (may need reduction due to additive myopathy risk with mTOR inhibitors)
- Diabetes medications (rapamycin may increase glucose; adjust metformin or insulin accordingly)
- Immunosuppressants (avoid concurrent use unless transplant patient)
¶ Mechanisms and Pathways
- Tau PET in CBS and PSP
- MRI Atrophy Patterns in CBS and PSP
- DTI White Matter Changes in CBS and PSP
- CSF Biomarkers for CBS and PSP
- Plasma Biomarkers for CBS and PSP
- Imaging Biomarkers for CBS and PSP
- PSP Biomarkers
- Low-Dose Lithium for Tauopathy
- Melatonin for Tauopathy
- Autophagy Enhancement for Tauopathy
- Mitochondrial Support Strategies for CBS and PSP
- Rapamycin for Tauopathy
- Senolytic Therapies for CBS and PSP
- Protective Strategies for CBS and PSP
- Exercise and Physical Activity for CBS and PSP
- CBS and PSP Treatment Rankings
- CBS and PSP Daily Action Plan
- CBS and PSP Rehabilitation Master Guide
- CBS and PSP Clinical Trials Guide
¶ Cell Type and Circuit Nodes
- Progressive Supranuclear Palsy Neurons
- Progressive Supranuclear Palsy Tau Neurons
- Substantia Nigra Neurons in Progressive Supranuclear Palsy
- Substantia Nigra in Corticobasal Degeneration
- Locus Coeruleus in Progressive Supranuclear Palsy
- Pedunculopontine Cholinergic Neurons in Progressive Supranuclear Palsy
- Subthalamic Nucleus in Progressive Supranuclear Palsy
- Red Nucleus Neurons in Progressive Supranuclear Palsy
- Globus Pallidus in Corticobasal Degeneration
- Striatal Interneurons in Corticobasal Degeneration
- Tauopathy Neurons
- Tauopathy-Associated Neurons